Dual-Headed Gamma Camera Coincidence Imaging: The Clinical Reality
- Three major developments have occurred that has lead to the wide spread use of F-18 FDG in PET imaging (mostly in the area of oncology)
- FDG regulations and its production
- 110 minute T1/2
- Commercial production
- Delivery to clinical sites within 2 – 4 hours from the site of production
- Approval by HCFA for reimbursement of F-18 FDG studies
- March 1998 Pulmonary nodules and staging malignant lesions in the lungs
- In 1999 three additional diseases where approved
- Recurrent colorectal cancer
- Recurrent malignant melanoma
- Malignant lymphoma
- Other indications are currently being reviewed
- Insurance carriers have followed HCFA’s recommendations
- Additional indications are reimbursed based on pre-approval by the referring physician
- Based on result in literature that identify F-18 FDG, as a tumor imaging agent, has an impact on the patient and is cost effectiveness
- Dual head, multi-function gamma cameras allows the use of single gamma and coincidence PET imaging